Needham Reiterates Buy on CRISPR Therapeutics, Maintains $82 Price Target

Benzinga Newsdesk www.benzinga.com Neutral 90.0%

Neg 0% Neu 90% Pos 0%

Needham analyst Gil Blum reiterates CRISPR Therapeutics (NASDAQ:CRSP) with a Buy and maintains $82 price target.

Comments

No comments yet. Be the first!